Renaissance Capital logo

Durata Therapeutics

Priced, Nasdaq: DRTX

Developing Phase 3 antibiotic candidate for acute skin infections.

Industry: Health Care

First Day Return: +0.4%

Developing Phase 3 antibiotic candidate for acute skin infections.
IPO Data
IPO Date 07/18/2012
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $68
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters Morristown, NJ, United States
Founded 2009
Employees at IPO 18
Website www.duratatherapeutics.com

Durata Therapeutics (DRTX) Performance